Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance

被引:25
|
作者
Barone, Giuseppe [1 ]
Barry, Ailish [1 ]
Bautista, Francisco [2 ]
Brichard, Benedicte [3 ]
Defachelles, Anne-Sophie [4 ]
Herd, Fiona [5 ]
Manzitti, Carla [6 ]
Reinhardt, Dirk [7 ]
Rubio, Pedro M. [8 ]
Wieczorek, Aleksandra [9 ]
van Noesel, Max M. [10 ,11 ]
机构
[1] Great Ormond St Hosp Sick Children, Dept Paediat Oncol, London, England
[2] Hosp Univ Nino Jesus, Dept Paediat Haematol & Oncol, Madrid, Spain
[3] Catholic Univ Louvain, Clin Univ St Luc, Brussels, Belgium
[4] Ctr Oscar Lambret, Pediat & AYA Oncol Unit, Lille, France
[5] Royal Aberdeen Childrens Hosp, Dept Paediat Oncol, Aberdeen, Scotland
[6] Ist Giannina Gaslini, Oncol Unit, Genoa, Italy
[7] Univ Hosp Essen, Pediat Hematol Oncol, Pediat 3, Essen, Germany
[8] Hosp Univ La Paz, Pediat Hematooncol Dept, Madrid, Spain
[9] Jagiellonian Univ Med Coll, Inst Pediat, Pediat Oncol Hematol Dept, Krakow, Poland
[10] Princess Maxima Ctr Pediat Oncol, Dept Solid Tumors, Heidelberglaan 25, NL-3584 CS Utrecht, Netherlands
[11] Univ Med Ctr Utrecht, Div Canc & Imaging, Utrecht, Netherlands
关键词
LONG-TERM INFUSION; ANTIBODY; INTERLEUKIN-2;
D O I
10.1007/s40272-021-00469-9
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Neuroblastoma is the most common extracranial solid tumour in children, accounting for 15% of all paediatric cancer deaths. High-risk neuroblastoma is a particularly challenging-to-treat form of disease that requires multimodality treatment, consisting of chemotherapy, surgery, high-dose chemotherapy with autologous haematopoietic stem cell rescue, radiotherapy and differentiation therapy. However, despite intense multimodal treatment regimens, the prognosis for this patient population remains poor. In recent years, immunotherapy with anti-disialoganglioside 2 (anti-GD2) antibodies was found to improve survival rates for patients with high-risk neuroblastoma. Based on studies led by the SIOPEN (International Society of Paediatric Oncology European Neuroblastoma) group, the anti-GD2 antibody dinutuximab beta was approved for use in high-risk neuroblastoma by the European Medicines Agency and has been implemented into the standard of care in many countries across Europe. However, immunotherapy with dinutuximab beta is associated with a number of adverse events that may be challenging for clinicians, such as pain, fever, hypersensitivity reactions and capillary leak syndrome. While these adverse events are considered manageable, there are currently no formal guidelines to support clinicians with their management. The aim of this article is to discuss the management of the most common adverse events encountered in clinical practice and to provide practical guidance to assist clinicians in minimising toxicity associated with dinutuximab beta.
引用
收藏
页码:537 / 548
页数:12
相关论文
共 50 条
  • [1] Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance
    Giuseppe Barone
    Ailish Barry
    Francisco Bautista
    Bénédicte Brichard
    Anne-Sophie Defachelles
    Fiona Herd
    Carla Manzitti
    Dirk Reinhardt
    Pedro M. Rubio
    Aleksandra Wieczorek
    Max M. van Noesel
    Pediatric Drugs, 2021, 23 : 537 - 548
  • [2] Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma
    Mora, Jaume
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (05) : 647 - 653
  • [3] Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma
    Spasov, Neofit
    Spasova, Mariya
    CASE REPORTS IN PEDIATRICS, 2021, 2021
  • [4] The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma
    Greenwood, Katie L.
    Foster, Jennifer H.
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1257 - 1262
  • [5] Dinutuximab: A Novel Immunotherapy in the Treatment of Pediatric Patients With High-Risk Neuroblastoma
    Bartholomew, Joy
    Washington, Tanea
    Bergeron, Sharon
    Nielson, Danelle
    Saggio, Jennifer
    Quirk, Lindsay
    JOURNAL OF PEDIATRIC ONCOLOGY NURSING, 2017, 34 (01) : 5 - 12
  • [6] Dinutuximab: A Review in High-Risk Neuroblastoma
    Sheridan M. Hoy
    Targeted Oncology, 2016, 11 : 247 - 253
  • [7] Dinutuximab beta in high-risk neuroblastoma: a profile of its use
    McKeage K.
    Lyseng-Williamson K.A.
    Drugs & Therapy Perspectives, 2018, 34 (7) : 281 - 287
  • [8] Dinutuximab: A Review in High-Risk Neuroblastoma
    Hoy, Sheridan M.
    TARGETED ONCOLOGY, 2016, 11 (02) : 247 - 253
  • [9] Correction to: Dinutuximab beta in high-risk neuroblastoma: a profile of its use
    Kate McKeage
    Katherine A. Lyseng-Williamson
    Drugs & Therapy Perspectives, 2018, 34 (7) : 288 - 288
  • [10] Dinutuximab beta in the treatment of high-risk neuroblastoma A follow-up of a case series in Bratislava
    Achbergerova, Monika
    Hederova, Stanislava
    Hraskova, Andrea
    Kolenova, Alexandra
    MEDICINE, 2022, 101 (04) : E28716